Testosterone labels shift after FDA safety review

The answer-first version: the FDA has now updated its public testosterone guidance after a safety review found no meaningful difference in major cardiovascular events in a large trial, while a newer 41-trial review found no statistically significant rise in major cardiovascular or prostate-cancer events. That does not turn testosterone therapy into a wellness shortcut. It means men who are actually being evaluated for low testosterone have a more current risk conversation to bring to a clinician.

The concrete data point to keep in your pocket: the FDA says the TRAVERSE trial tracked more than 5,200 men and reported major adverse cardiovascular events in 7.0% of men using AndroGel versus 7.3% in the placebo group. In June 2026, FDA requested prescribing-information updates that remove the older limitation saying safety and effectiveness had not been established for age-related hypogonadism, and revise safety information tied to prostate cancer and benign prostatic hyperplasia.

What changed in the label conversation

The FDA's testosterone information page now says approved testosterone products remain for men with low testosterone linked to an associated medical condition, and it still says no FDA-approved testosterone product is approved for men with low testosterone who lack an associated condition. That line matters because the consumer market around "low T" often blurs medical treatment, aging, libido, gym culture and influencer medicine into one foggy pitch.

The agency's 2025 class-wide labeling action had already removed boxed-warning language about increased cardiovascular risk after review of TRAVERSE, while adding blood-pressure warnings based on ambulatory blood pressure monitoring studies. The 2026 update goes further on age-related hypogonadism language and prostate/BPH warnings, according to FDA's current testosterone page and the related HHS announcement linked there.

Healthline's June 23 report described the HHS move as a proposed label update that could expand access for some men with idiopathic or age-related hypogonadism. I would phrase that more cautiously for readers: access may widen, but the practical standard should still be diagnosis first, monitoring second, marketing never.

The evidence is reassuring, not a free pass

The new peer-reviewed piece worth watching is a 2026 systematic review and meta-analysis in the International Journal of Impotence Research. The authors reviewed 41 randomized controlled trials including 11,161 participants. Their pooled estimates did not show a statistically significant increase in major adverse cardiovascular events, prostate cancer events or clinically significant prostate cancer events among men receiving testosterone therapy. For major adverse cardiovascular events, the reported odds ratio was 0.83 with a 95% confidence interval of 0.52 to 1.32. For prostate cancer events, it was 0.88 with a 95% confidence interval of 0.52 to 1.51.

The authors' own caveat is the one readers should hear: the evidence supports short- to mid-term safety, but long-term data are still needed. That caveat is not fine print. Men may use therapy for years, not just the length of a trial. And testosterone can still carry other issues, including blood pressure changes, erythrocytosis monitoring, fertility suppression and prostate-symptom follow-up, depending on the patient.

So the useful takeaway is not "testosterone is safe." Sourced or it didn't happen — and the sourced version is narrower: for appropriately selected men in studied settings, the strongest recent data are less alarming on heart attack, stroke and prostate-cancer signals than older warning language suggested.

For readers considering an appointment, the short list is simple:

• Ask whether symptoms match a true hypogonadism workup, not just a single low number.
• Ask for repeat morning testosterone testing and the likely cause of the low level.
• Ask how blood pressure, hematocrit, prostate symptoms and fertility goals will be monitored.
• Be skeptical of any clinic that sells treatment before it explains the diagnosis.

Men's health gets hurt by two opposite myths: that every fatigue problem is testosterone, and that testosterone therapy is automatically reckless. The FDA's newer language and the 2026 trial review point to the harder, better middle: more individualized care, with fewer stale warnings and more honest monitoring.

Source log

• FDA Testosterone Information page, current guidance and June 2026 requested label updates: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/testosterone-information
• FDA 2025 class-wide labeling changes after TRAVERSE and blood-pressure monitoring studies: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
• García-Becerra et al., 2026 systematic review/meta-analysis in International Journal of Impotence Research: https://www.nature.com/articles/s41443-026-01237-4
• Healthline report on the HHS/FDA label-update move, used as major-outlet context: https://www.healthline.com/health-news/hhs-updates-testosterone-therapy-warning-labels

What's shaky: FDA's HHS press release was linked from FDA but blocked extraction in my run, so the draft relies on FDA's own testosterone-information page and extracted FDA labeling page for the agency facts, with Healthline used only for secondary context.